Drug Shortage Report for CONTRAVE
| Report ID | 218165 |
| Drug Identification Number | 02472945 |
| Brand name | CONTRAVE |
| Common or Proper name | CONTRAVE |
| Company Name | BAUSCH HEALTH, CANADA INC. |
| Market Status | MARKETED |
| Active Ingredient(s) | BUPROPION HYDROCHLORIDE NALTREXONE HYDROCHLORIDE |
| Strength(s) | 90MG 8MG |
| Dosage form(s) | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL ORAL |
| Packaging size | n/a |
| ATC code | A08AA |
| ATC description | |
| Reason for shortage | Delay in shipping of the drug. |
| Anticipated start date | 2024-02-29 |
| Actual start date | |
| Estimated end date | 2024-03-08 |
| Actual end date | 2024-02-01 |
| Shortage status | Avoided shortage |
| Updated date | 2024-02-05 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 2150 BOUL. ST-ELZEAR OUEST LAVAL, QUEBEC CANADA H7L 4A8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2024-02-05 | French | Compare |
| v3 | 2024-02-05 | English | Compare |
| v2 | 2024-02-01 | French | Compare |
| v1 | 2024-02-01 | English | Compare |
Showing 1 to 4 of 4